In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer

Executive Summary

The broad partnership to discover and commercialize drugs in vascular biology, inflammatory diseases, and oncology announced this month between GlaxoSmithKline and Exelixis recalls the halcyon big-deal era of 2000. But the new deal's objects, structure, and value confirm industry changes in the last two-plus years: a focus on compounds, not discovery-stage science; that Big Pharma's poor R&D productivity is becoming obvious even to its research leadership; and that the biotechs who can sign these kinds of deals combine a set of discovery technologies into a package that, theoretically, produces clinical compounds.
Advertisement

Related Content

End of an Era for GSK and Exelixis
Feeding the Machine: Exelixis Buys X-Ceptor
The Cooperative, Competitive Future of Pharma R&D
The Infrastructure Dilemma
Why Deal Accounting Matters
Why Deal Accounting Matters
Roche Bucks the Trend, with Early-Stage Deals
Roche Bucks the Trend, with Early-Stage Deals
Exelixis: Bartering for Growth
Exelixis: Bartering for Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel